Oculus Research

Executive Summary

Oculus Research is a specialized clinical research organization (CRO) focused on ophthalmology and broader therapeutic areas. Founded in 2014 and based in Menlo Park, California, the company conducts clinical trials for pharmaceutical and medical device sponsors, managing studies from early phases through FDA approval. With a track record of contributing to nine ophthalmic treatments reaching the market, Oculus Research has established itself as a key partner in the ophthalmic drug development ecosystem. The company's expertise spans patient enrollment, study management, and regulatory support, positioning it to benefit from the growing demand for specialized CRO services as the ophthalmology pipeline expands. As a private company, Oculus Research operates with flexibility and a focus on high-quality trial execution, which has enabled it to build long-term relationships with sponsors.

Upcoming Catalysts (preview)

• Q2 2026New contract wins with leading pharma for ophthalmic trials70% success
• Q3 2026FDA approval of a drug candidate for which Oculus managed pivotal trials60% success
• H2 2026Expansion into gene therapy or cell therapy clinical services for retinal diseases50% success